



## AIRA 2023 CALL FOR ABSTRACTS

Join us for the AIRA 2023 National Meeting May 2-4 in San Diego, California. Members of the IIS community will convene to advance IIS together. Through both formal presentations and informal discussions, attendees will have an opportunity to strengthen long-term partnerships, develop new relationships, gain professional education and training, and learn from one another. AIRA invites you to submit abstracts for consideration. During the submission process, you will be given the opportunity to select your preferred presentation format.

### SUBMISSION GUIDELINES

- The deadline for submission is **Sunday, January 8 by 11:59 p.m. ET.**
- Abstracts must be submitted online.
- All authors and presenters are required to complete a conflict of interest disclosure.
- All presenters are required to register to attend the AIRA 2023 National Meeting and to pay the applicable registration fee.
- Abstracts should closely describe the material to be presented or covered.
- Please note that AIRA will have final content approval rights.

### KEY DATES

**Meeting Registration Opens**

Wednesday, November 16

**Call for Abstracts Opens**

Monday, October 31

**Call for Abstracts Closes**

Sunday, January 8

**Abstract Review Period**

Monday, January 9 –

Friday, February 10

**Speaker Acceptance Notifications**

Monday, February 13

### QUESTIONS?

Contact **Carmela Gupta**

Director of Education & Outreach

[cgupta@immregistries.org](mailto:cgupta@immregistries.org)

**CLICK HERE**

to submit your abstract for the  
AIRA 2023 National Meeting



**AIRA**  
AMERICAN IMMUNIZATION  
REGISTRY ASSOCIATION



## SUBMISSION OVERVIEW

AIRA invites meeting attendees to submit abstracts to be shared during the meeting's breakout sessions. These breakouts take place concurrently across multiple tracks based on topic.

A breakout session may include:

- 20-minute presentations
- 20-minute group discussions

## AIRA invites submissions for the following:

	Presentation Length	Quick Definition
<b>1 Breakout Session Presentation</b>	20 minutes	Accepted presentations will be grouped into breakout sessions by meeting organizers. Presenters will each have 20 minutes for their presentation with additional time for Q&A incorporated into each session.
<b>2 Lead a Group Discussion</b>	20 minutes	Accepted discussion topics will be led by the submitter. Those leading the discussion will have 20 minutes to lead a group discussion during a breakout session.

# BREAKOUT TOPICS FOR SUBMISSION

## DATA EXCHANGE AND DATA SHARING

Real-life examples of the challenges and successes of data reporting and data sharing; best practices supporting data reporting; provider site onboarding and participation; data visualization; bulk query and data lakes; data sharing with non traditional partners.

## IMMUNIZATION DATA AND PRACTICES

Innovative ways to improve the quality and completeness of immunization data and upgrade infrastructure and data practices; reminder/recall; leveraging current funding opportunities for IIS; data modernization.

## OUTBREAK AND PANDEMIC RESPONSE

Monkeypox response, COVID-19 lessons learned, and best practices; sustainability; vaccine administration tools and IIS integration (e.g., VAMS, PrepMod); vaccine credentialing; consumer access to IIS; etc.

## SYSTEMS INTEGRATION

Successful ways of integrating with other systems and programs such as the DMV, disease surveillance, Medicaid, Smarty, US postal service forwards, PPRL, IZ Gateway/IIS-IIS exchange, etc.

## OTHER

Although so much of our recent work has been focused on responding to monkeypox and COVID-19, we'd still love to hear about the other work that is crucial to the IIS community. If your content doesn't fit any of the topics, this category is for you.



# SUBMISSION PREVIEW

ONLY CONTENT SUBMITTED VIA THE AIRA WEBSITE WILL BE REVIEWED

[www.airanationalmeeting.org](http://www.airanationalmeeting.org)

NOTE: For purposes of clarity, Submission Preview does not exactly match the order in which you will enter information when submitting your content.

## SUBMITTER DETAILS

Please provide complete information. This person will be the primary contact for this submission. AIRA will send all correspondence to this individual, and the person will be expected to communicate any questions or other instructions to co-presenters/co-authors.

### Submitter Details

\*Email

\*First Name

\*Last Name

\*Job Title

\*Organization

\*City

\*US State/Territory

ZIP Code

Country

Phone Number

Advanced Degree 1

Advanced Degree 2

Other Advanced Degree

\*Biography  
(max. 300 characters)

Please do not enter placeholder text. This is your only opportunity to provide this information.

## PRESENTER DETAILS

Use the submitter as the main author?

Yes  No

(If answer is no, enter Main Author Details)

### Main Author Details

\*Email

\*First Name

\*Last Name

\*Job Title

\*Organization

\*City

\*US State/Territory

\*Country

Advanced Degree 1

Advanced Degree 2

Other Advanced Degree

\*Is this author a presenter?  Yes  No

\*Biography  
(max. 300 characters)

Please do not enter placeholder text. This is your only opportunity to provide this information.





# SUBMISSION PREVIEW

ONLY CONTENT SUBMITTED VIA THE AIRA WEBSITE WILL BE REVIEWED

[www.airanationalmeeting.org](http://www.airanationalmeeting.org)

## CO-AUTHOR DETAILS

(maximum of 6 co-authors per submission)

\*Email

\*First Name

\*Last Name

\*Job Title

\*Organization

\*City

\*US State/Territory

\*Country

Advanced Degree 1

Advanced Degree 2

Other Advanced Degree

Is this author a presenter?  Yes  No

Lead Presenter

## CONFLICT OF INTEREST DISCLOSURE

All authors and presenters are expected to disclose to the audience any financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in the proposed presentation/group discussion (*other relationships may include grants or research support or being an employee, consultant, contractor to a government agency, or major stockholder*).

This disclosure should cover relationships that were in place at the time of and/or 12 months preceding the activity.

The intent of this disclosure is to provide the audience with information which they can use to make their own judgments to determine whether the speaker's interests or relationships may influence the presentation.

**\*Will your presentation include any discussion of commercial products or commercial service provider work products?**

Yes  No

(If answer is yes)

**\*Do you or any of the authors/presenters have a significant financial interest or other relationship with the manufacturer's product you will discuss?**

Yes  No

**\*Please list the commercial product(s), manufacturer(s), and/or providers of commercial service(s) and describe the nature of the relationships.**





# SUBMISSION PREVIEW

ONLY CONTENT SUBMITTED VIA THE AIRA WEBSITE WILL BE REVIEWED

[www.airanationalmeeting.org](http://www.airanationalmeeting.org)

## PRESENTATION TYPES

Please indicate which presentation type you are submitting by selecting "Add"

- Standard Presentation
- Lead a Group Discussion

## PRESENTATION TYPE DETAILS

Options below vary by presentation type selected.

### 1 Standard Presentation

**\*Abstract Title (75 characters)**

**\*Please confirm presentation type**

- Standard Presentation
- Lead a Group Discussion

**\*All presentations will be offered in person only. There will not be a virtual component of the meeting in 2023. Please confirm that you are willing to present in person.**

- Yes, I confirm that I am able to present in person
- No, I will not be able to present in person

**\*Topic**

- Data Exchange and Data Sharing
- Immunization Data and Practices
- Outbreak and Pandemic Response
- Systems Integration
- Other

## ASSISTANCE REQUEST

Any information you would like to share with meeting organizers

### 2

### Lead a Group Discussion

**\*Submission Title (75 characters)**

**\*Please confirm presentation type**

- Standard Presentation
- Lead a Group Discussion

**\*All Lead a Group Discussions will be offered in person only. There will not be a virtual component of the meeting in 2023. Please confirm that you are willing to present in person.**

- Yes, I confirm that I am able to present in person
- No, I will not be able to present in person

**\*Topic**

- Data Exchange and Data Sharing
- Immunization Data and Practices
- Outbreak and Pandemic Response
- Systems Integration
- Other

## ASSISTANCE REQUEST

Any information you would like to share with meeting organizers



# SUBMISSION PREVIEW

ONLY CONTENT SUBMITTED VIA THE AIRA WEBSITE WILL BE REVIEWED

[www.airanationalmeeting.org](http://www.airanationalmeeting.org)

## INSTRUCTIONS

Describe what you'd like to cover in your presentation. Consider including sections that define the background, methods, implementation, results, and conclusions of your project or study, as applicable. Abstracts/presentations that lead to concrete and useful takeaways for attendees will be prioritized for inclusion. AIRA may follow up with you to gather additional details regarding your proposed abstract. This text will be evaluated by reviewers and will be shared with meeting attendees if your abstract is selected.

(max 300 words)

NOTE: You will have the opportunity to review prior to final submission.

### QUESTIONS?

Contact **Carmela Gupta**  
Senior Program Manager  
[cgupta@immregistries.org](mailto:cgupta@immregistries.org)



**AIRA**  
AMERICAN IMMUNIZATION  
REGISTRY ASSOCIATION

*Advancing IIS Together*